Vaginal Microbiota and Mucosal Immune Markers in Women With Vulvovaginal Discomfort
Overview
Authors
Affiliations
Background: Up to 30% of women with vaginal symptoms are not assigned a diagnosis after standard diagnostic assessment.
Methods: We compared premenopausal women with idiopathic vaginitis (IV) or vulvodynia (VVD) to healthy controls. Microbiota were characterized using rRNA sequencing. Cytokines/chemokines (IL-10, IL-1α, IL-1β, IL-6, IL-8, IL-2, IL-18, IL-4, IL-9, and IL-13) were measured in vaginal lavage fluid using the Meso Scale Discovery platform or ELISA (IL-1ra). Immunoglobulins were measured in vaginal lavage fluid using a bead-based immunoassay (Millipore). Cases and controls were compared using Kruskal-Wallis, analysis of variance, and linear regression or (for microbiome composition) the Bray-Curtis dissimilarity statistic.
Results: We compared 20 women with IV, 30 with VVD, and 52 controls. Most (80%) had greater than 90% 16S rRNA gene sequences from Lactobacillus crispatus, L. jensenii, L. gasseri, or L. iners. In analyses adjusted for age and hormonal contraception (HC), Gardnerella vaginalis was less prevalent and abundant in women with VVD (2/30, 7%) versus controls (16/52, 31%) or IV (5/20, 25%) (P = 0.030). Bray-Curtis dissimilarity was not significantly different between IV and controls or VVD. Fungal sequences were only detected in 5 participants: 2 control, 1 IV, 2 VVD. In univariate analysis, cytokines were not associated with diagnosis. Median vaginal concentration of IgE (but not other immunoglobulins) was lower in women with VVD (P = 0.006).
Conclusions: Minimal differences in vaginal microbiota and inflammatory markers between women with IV, VVD or controls suggest no striking association between vaginal bacteria, fungi or inflammation and diagnosis in these women.
Robbins S, Brown S, Stennett C, Tuddenham S, Johnston E, Wnorowski A PLoS One. 2024; 19(2):e0296346.
PMID: 38315688 PMC: 10843103. DOI: 10.1371/journal.pone.0296346.
Comparison of vaginal microbiota between women with inflammatory bowel disease and healthy controls.
Bar O, Sudhof L, Yockey L, Bergerat A, Moriel N, Andrews E PLoS One. 2023; 18(11):e0284709.
PMID: 38019873 PMC: 10686494. DOI: 10.1371/journal.pone.0284709.
Kim Y, Bergerat-Thompson A, Mitchell C PLoS One. 2023; 18(4):e0283215.
PMID: 37058538 PMC: 10104322. DOI: 10.1371/journal.pone.0283215.
Bloom S, Mafunda N, Woolston B, Hayward M, Frempong J, Abai A Nat Microbiol. 2022; 7(3):434-450.
PMID: 35241796 PMC: 10473153. DOI: 10.1038/s41564-022-01070-7.
Usyk M, Schlecht N, Pickering S, Williams L, Sollecito C, Gradissimo A Nat Commun. 2022; 13(1):233.
PMID: 35017496 PMC: 8752746. DOI: 10.1038/s41467-021-27628-3.